Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
© 2019 Deerochanawong et al. Aim: Liraglutide, a once-daily subcutaneous glucagon-like peptide-1 (GLP-1) agonist, is approved for treatment of hyperglycemia in patients with type 2 diabetes mellitus (T2DM). For patients with established cardiovascular diseases, liraglutide has also been shown to red...
Saved in:
| Main Authors: | , , , , |
|---|---|
| 格式: | 雜誌 |
| 出版: |
2019
|
| 主題: | |
| 在線閱讀: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85071682129&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/66653 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
| 機構: | Chiang Mai University |